Please assess the completion status of the following clinical trial:

Trial Title: S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed epidermoid carcinoma of the penis~  * Distant metastases (M1) OR~ * Pathologically confirmed regional nodal metastases (N1-3)~* Measurable disease~  * Soft tissue disease irradiated within the past 2 months is not considered measurable disease~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* White blood cell (WBC) count at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) no greater than 2.5 times ULN~  * If SGOT is greater than ULN, alkaline phosphatase must be no greater than 2.5 times ULN~* Alkaline phosphatase no greater than 4 times ULN~  * If alkaline phosphatase is greater than ULN, SGOT must be no greater than 1.5 times ULN~Renal~* Not specified~Other~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission~* No grade 2 or greater peripheral neuropathy~* No hypersensitivity to drugs formulated with polysorbate 80 (e.g., recombinant interferon alfa-2a, multivitamin infusion, etoposide, infliximab, or NovoSeven factor)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for penile cancer~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 28 days since prior radiotherapy and recovered~Surgery~* Not specified

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).